Cure8 news brief
The study links a common plant compound (oxalate) to higher stool levels and worse inflammation in IBD, suggesting diet and gut handling of oxalate could affect disease activity and that microbiome-targeted strategies might help.
Adults with Crohn's disease or ulcerative colitis, IBD clinicians and dietitians, and researchers focused on diet–microbiome–immune interactions or biomarkers.
The study measured gene expression, stool oxalate, and diet in IBD patients and controls, used DNA metabarcoding to verify plant intake, and performed complementary mouse and cell-culture experiments. Crohn's patients had higher stool oxalate despite similar plant consumption, suggesting a defect in oxalate handling rather than just diet.
In mice, dietary oxalate worsened colitis and reduced survival in susceptible models. The authors note that oxalate-degrading gut bacteria (for example, Oxalobacter formigenes) are depleted in IBD and propose microbiome-based approaches as a possible therapeutic angle.
This is not a recommendation to stop eating plants: the authors say it's possible to keep a nutritionally complete, plant-forward diet while lowering oxalate intake, and they call for larger, longitudinal human studies integrating stool oxalate, molecular profiling, and microbiome data before changing clinical guidance.
These results combine human tissue and stool measurements with mouse and cell experiments. Authors recommend further validation in larger, longitudinal human cohorts before changing clinical practice; they also highlight microbiome-based strategies as a possible therapeutic path.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.
Vitamin D may support intestinal barrier integrity and immune regulation—pathways central to mucosal healing and disease control in IBD. Understanding the evidence helps patients and clinicians consider vitamin D as a...
Vitamin D appears linked to immune regulation, gut barrier health, and the microbiome—processes relevant to IBD and other intestinal disorders. Understanding this could affect how clinicians monitor and study vitamin D...
